The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer - Results from a 4-month pre-radical prostatectomy study

Prostate

Volumn 66, Issue 15, 2006, Pages 1674-1685

  Gleave, M ^a   Qian, J ^b   Andreou, C ^c   Pommerville, P ^d   Chin, J ^e   Casey, R ^f   Steinhoff, G ^g   Fleshner, N ^h   Bostwick, D ^b   Thomas, L ⁱ   Rittmaster, R ^j  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BOSTWICK LABORATORIES   (United States)

^c SURREY MEMORIAL HOSPITAL   (Canada)

^d Can Med Clinical Research Inc   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f Female/Male Health Centre   (Canada)

^g Dr Steinhoff Clinical Research   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

5 alpha reductase; Apoptosis; Gleason score; Proliferation; Prostate cancer; Treatment

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; AZASTEROID; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

ABDOMINAL DISTENSION; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER LOCALIZATION; CELL PROLIFERATION; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GLEASON SCORE; HEADACHE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN; PERINEUM; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SEMEN ABNORMALITY; TREATMENT OUTCOME; TUMOR VOLUME; ADENOCARCINOMA; BLOOD; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROSTATE; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; AZASTEROIDS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 33750486196     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20499     Document Type: Article

References (41)

1. Cabot A. The question of castration for enlarged prostate. Ann Surg 1896;24:265.
2. Huggins C, Hodges CV. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293.
3. Huggins C, Stevens R, Hodges C. Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-233.
4. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5alpha-reductase. Endocrinology 1999;140:4509-4515.
5. Lamb JC, Levy MA, Johnson RK, Isaacs JT. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate 1992;21(1):15-34.
6. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995;45(2):282-290.
7. Zaccheo T, Giudici D, di Salle E. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate 1998;35(4):237-242.
8. Zaccheo T, Giudici D, di Salle E. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat. J Steroid Biochem Mol Biol 1998;64(3-4):193-198.
9. Zaccheo T, Giudici D, di Salle E. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate 1997;30(2):85-91.
10. Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D, Ng J, Gormley GJ. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148(4):1201-1204.
11. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middleton R, Ng J, Ferguson D, Gormley G. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45(3):491-497.
12. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
13. Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: Current state of knowledge. J Urol 2005;174(6): 2098-2104.
14. Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999;53(4):696-700.
15. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81(2):814-819.
16. Civantos F, Watson RB, Pinto JE, Korman RB, Soloway MS. Finasteride effect on prostatic hyperplasia and prostate cancer: A comparative clinico-pathologic study of radical prostatectomies. J Urol Pathol 1997;6:1-14.
17. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172(3):915-919.
18. Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 2005;65(1):76-82.
19. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172(4 Pt 1):1314-1317.
20. Rittmaster RS, Thomas LN, Wright AS, Murray SK, Carlson K, Douglas RC, Yung J, Messieh M, Bell D, Lazier CB. The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer. J Urol 1999;162(6):2165-2169.
21. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-2184.
22. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-441.
23. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175(5):1657-1662.
24. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98(16):1128-1133.
25. Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: A detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26(11):1400-1413.
26. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003;54(3):212-219.
27. Ohlson N, Wikstrom P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005;62(4):307-315.
28. Miyata Y, Kanda S, Sakai H, Hakariya T, Kanetake H. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment. Urology 2005;65(6):1238-1243.
29. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP 3rd. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 2000;89(2):412-423.
30. An G, Meka CS, Bright SP, Veltri RW. Human prostate-specific transglutaminase gene: Promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology 1999;54(6):1105-1111.
31. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15(3):233-250.
32. Piacentini M, Autuori F, Dini L, Farrace MG, Ghibelli L, Piredda L, Fesus L. "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor-stimulation. Cell Tissue Res 1991;263(2):227-235.
33. Trojan L, Thomas D, Friedrich D, Grobholz R, Knoll T, Alken P, Michel MS. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: An immunohistochemical and clinical evaluation. Anticancer Res 2004;24(3a):1651-1656.
34. Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, Fracchia JA. Decreased suburethral prostatic microvessel density in finasteride treated prostates: A possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002;167(4):1731-1733.
35. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, Fracchia JA. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169(1):20-23.
36. Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 2005;96(9):1319-1322.
37. Kaya C, Ozyurek M, Turkeri LN. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: A preliminary study. Int J Urol 2005;12(2):194-198.
38. Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999;85(8):1822-1827.
39. Ives EP, Gomella LG, Halpern EJ. Effect of dutasteride therapy on Doppler US evaluation of prostate: Preliminary results. Radiology 2005;237(1):197-201.
40. Scardino PT. The prevention of prostate cancer-the dilemma continues. N Engl J Med 2003;349:293-295.
41. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Evidence for a biopsy-derived grade artifact among larger prostate glands. J Urol 2006;175(2):505-509.